# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Data presented at the 14th International Congress on AutoimmunityEncouraging preclinical data observed to date on par with OFEV...
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant N...
GRI Bio (NASDAQ:GRI) reported quarterly losses of $(0.46) per share. This is a 98.77 percent increase over losses of $(37.31) p...
Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innov...